Are Auto Stem Cell Transplants More Effective On Outpatient Basis?

A new study suggests that Autologous hematopoietic cell transplantations (Auto-HCT) could be more effective across a number of different measurements if performed on an outpatient basis, compared to an inpatient basis.

Auto-HCT has not traditionally been regarded as a procedure that is done on an outpatient basis. However, this appears to be changing, and more and more patients are undergoing the procedure and then going home. Researchers reporting in the journal Bone Marrow Transplantation decided to carry out a retrospective analysis and determine if one was better than the other.

Researchers from the Division of Hematology and Oncology, Medical College of Wisconsin in Milwaukee compared outcomes in 230 patients who underwent Auto-HCT either as inpatients or outpatients for either lymphoma or myeloma.

What they found included the following:

Median time to neutrophil recovery:

  • Outpatients: 10 days
  • Inpatients: 11 days

Median time to platelet recovery

  • Outpatients: 19 days
  • Inpatients: 20 days

Two-year progression free survival:

  • Outpatient: 62 percent
  • Inpatient: 54 percent

One and two year overall survival rates:

  • Outpatients: 97 percent and 83 percent
  • Inpatients: 91 percent and 80 percent

These data and others led them to conclude that "with daily outpatient evaluation and aggressive supportive care, outpatient Auto-HCT can result in excellent outcomes for myeloma and lymphoma patients."

Source: Bone Marrow Transplantation

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap